50.0% volume surge: 1H3.SI stock at S$0.003 on SES, watch 12-month forecast
The 1H3.SI stock led high-volume movers today after a 50.0% intraday jump to S$0.003 on the Singapore Exchange (SES), backed by 50,442,200 shares traded. The move pushed the stock well above its 50-day average of S$0.00186 and ahead of the 200-day average S$0.00270. As a low‑priced healthcare name with a market cap of S$8,591,642.00, Clearbridge Health Limited (1H3.SI) attracted speculative flows and liquidity-driven trading. We break down the volume drivers, valuation, Meyka AI grade, and what the 1H3.SI stock outlook implies for traders and longer-term investors
Trading snapshot: 1H3.SI stock volume and price action
Today Clearbridge Health Limited (1H3.SI) closed at S$0.003, up 0.001 or 50.0%, with a session range S$0.002–S$0.003. Volume ran at 50,442,200 shares vs average volume 7,647,301, a relVolume of 1.28, marking an outsized liquidity event. The share count is 4,295,820,825 outstanding and market cap is S$8,591,642.00. High turnover at this price level often reflects newsflow, block trades, or momentum trading in micro‑cap names on SES.
Why volume mattered today for 1H3.SI stock
The surge in volume amplified a small price move into a notable percentage change because the stock trades at three decimals. Volume reached 50.44M versus a 50‑day average of 7.65M, suggesting either accumulation by speculators or short-term repositioning. For liquidity traders, the gap between the year low S$0.001 and year high S$0.005 shows the stock can swing wide on modest capital flows. Higher turnover improves tradability but raises short-term volatility risk for investors in SGD.
Valuation and fundamentals: key ratios for 1H3.SI stock
Clearbridge Health reports trailing metrics that show a mixed picture: price‑to‑sales 1.16, price‑to‑book 0.27, and current ratio 1.73. The company recorded revenue S$9.90M in 2024 with a loss narrowing to S$3.61M. Return on equity is negative at -19.95%, while debt‑to‑equity is modest at 0.12. These figures point to a low PB valuation but persistent profitability challenges in the medical diagnostics and clinics segment.
Meyka AI rates 1H3.SI with a score out of 100 and technical read
Meyka AI rates 1H3.SI with a score out of 100: 57.36 (C+) — HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Technical indicators show RSI 51.74 and ADX 66.13, indicating strong trend momentum during the volume event. Traders should note large on‑book volume (OBV negative historically) and a 50‑day moving average gap of S$0.00186, which increases mean‑reversion probability.
Meyka AI’s forecast model projects future price levels for 1H3.SI stock
Meyka AI’s forecast model projects a 12‑month median target of S$0.00933. Compared with the current price S$0.003, that implies an implied upside of 211.08%. The model also offers multi‑year paths: 3‑yr S$0.02420, 5‑yr S$0.03904. Forecasts are model‑based projections and not guarantees. Use them as scenario inputs, not certainty.
Risks and catalysts shaping the 1H3.SI stock outlook
Key catalysts include operational recovery in clinic visits, new imaging contracts across Southeast Asia, and clearer guidance at the next earnings release dated 2026‑02‑27. Primary risks are continued net losses, thin free cash flow per share (-0.00076) and a small market cap that leaves the stock sensitive to block trades. Watch regulatory updates and any changes to strategic investments that alter the balance sheet.
Final Thoughts
Clearbridge Health (1H3.SI) moved into our high‑volume movers list because a 50.0% intraday rise on 50,442,200 shares materially changed liquidity and short‑term technicals. The stock trades on the Singapore Exchange (SES) at S$0.003 and exhibits deep volatility against a narrow market cap of S$8,591,642.00. Meyka AI’s forecast model projects S$0.00933 over 12 months, implying +211.08% from today’s price, while longer horizons show larger modelled gains. Our proprietary grade states: Meyka AI rates 1H3.SI with a score out of 100 — 57.36 (C+) — HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Traders should treat the move as liquidity‑led rather than fundamental confirmation. For active traders, the high volume opens short‑term opportunities but also raises execution risk; longer‑term investors should wait for consistent margin improvement or clearer earnings guidance. For company details see Clearbridge Health and the latest financials at StockAnalysis. Meyka AI provides this as an AI‑powered market analysis platform; forecasts and grades are model outputs and not investment advice.
FAQs
What drove the volume spike in 1H3.SI stock today?
The volume spike to 50.44M shares likely reflects speculative trading and liquidity chasing at a micro‑cap price point. There was no single public catalyst; monitor company announcements and order flow for confirmation.
What is the Meyka AI 12‑month forecast for 1H3.SI stock?
Meyka AI’s forecast model projects a 12‑month target of S$0.00933, implying about +211.08% versus the current S$0.003. Forecasts are projections, not guarantees.
Is 1H3.SI stock a buy after today’s move?
Given the C+ (57.36) HOLD grade and negative profitability metrics, we recommend caution. High volume improves liquidity but does not remove fundamental risks such as ongoing losses and thin free cash flow.
When is Clearbridge Health’s next earnings announcement?
Clearbridge Health has an earnings announcement scheduled for 2026‑02‑27. Investors should review that release for updated revenue, margins, and guidance.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
